← Oncology Approval Tracker

FDA DECISION ·

Braftovi + Mektovi

encorafenib + binimetinib · Array BioPharma / Pfizer

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic NSCLC and BRAF V600E confirmed by an FDA-approved test.

LAMPGEN ANALYSIS

Why it matters

The combination extended dual BRAF and MEK inhibition into a biomarker-selected lung cancer setting.

What research teams should watch

Check the exact BRAF variant and document baseline organ assessments appropriate to the two-drug regimen.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Biomarker-selected advanced NSCLC

PRIMARY RECORDS

Sources